CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
Checkpoint blockade immunotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02843165
NCT02843165Phase 2Completed
CompareCT.gov

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

University of California, San Diego·interventional·Posted Jul 25, 2016·Updated Sep 30, 2025

In Brief

A Phase 2 clinical trial evaluating Checkpoint blockade immunotherapy and Checkpoint blockade immunotherapy plus SBRT for Metastatic Cancer. Completed, enrolled 106 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in patients with advanced metastatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 25, 2016
Enrollment StartSep 2, 2016
Primary CompletionAug 16, 2021
Study CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.9 years ago

Interventions

Checkpoint blockade immunotherapydrug

Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)

Checkpoint blockade immunotherapy plus SBRTradiation

SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)